SCM
VRDN icon

Sterling Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Sterling Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Buy
1,662
+676
+69% +$10.9K ﹤0.01% 1711
2026
Q1 		$19.3K Sell
986
-384
-28% -$11.4K ﹤0.01% 2047
2025
Q4 		$42.6K Buy
1,370
+230
+20% +$6.31K ﹤0.01% 1855
2025
Q3 		$24.6K Buy
1,140
+623
+121% +$11.2K ﹤0.01% 2043
2025
Q2 		$7.23K Buy
517
+121
+31% +$1.64K ﹤0.01% 2313
2025
Q1 		$5.34K Sell
396
-271
-41% -$4.62K ﹤0.01% 2139
2024
Q4 		$12.8K Buy
667
+567
+567% +$12.3K ﹤0.01% 2053
2024
Q3 		$2.27K Buy
+100
New +$1.64K ﹤0.01% 2128

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sterling Capital Management's VRDN Position: Q2 2026 in Review

Sterling Capital Management increased its Viridian Therapeutics (VRDN) stake by 69% in Q2 2026, buying an estimated $10.9K and bringing the position to 1,662 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Sterling Capital Management first reported a position in VRDN in Q3 2024 and has held it in 8 quarters since. The position peaked at $42.6K in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Sterling Capital Management held 1,662 shares of Viridian Therapeutics worth $30.5K as of Q2 2026.
  • Sterling Capital Management bought 676 Viridian Therapeutics shares in Q2 2026, an estimated $10.9K.
  • Viridian Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1711 holding.
  • Sterling Capital Management first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Viridian Therapeutics position peaked at $42.6K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.